Bridgebio Pharma Inc – (BBIO, +N, Jan 4th)
Six Non-Executives bought a total of $2.8 million of stock across a series of purchases on the 29th and 30th December at approx $14. In each case, this is their first purchase in the stock having joined the board in 2020 or 2021 (James Momtazee is the exception, he joined in 2016).
The shares have been extremely weak since disappointing clinical trial results in December 2021. Whilst this is likely a coordinated set of purchases and we would like to see executives join the buying, this is still a meaningful cluster of purchases.
We are ranking the stock +N.